These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3055176)

  • 1. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins.
    Sanders WE; Sanders CC
    Rev Infect Dis; 1988; 10(4):830-8. PubMed ID: 3055176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical importance of inducible beta-lactamases in gram-negative bacteria.
    Sanders CC; Sanders WE
    Eur J Clin Microbiol; 1987 Aug; 6(4):435-8. PubMed ID: 3311737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins.
    Dworzack DL; Pugsley MP; Sanders CC; Horowitz EA
    Eur J Clin Microbiol; 1987 Aug; 6(4):456-9. PubMed ID: 3499316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.
    Livermore DM
    Eur J Clin Microbiol; 1987 Aug; 6(4):439-45. PubMed ID: 3311738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The threat of resistance to the new oral cephalosporins.
    Cullmann W
    Chemotherapy; 1992; 38 Suppl 2():10-7. PubMed ID: 1516458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of inducible beta-lactamases in gram-negative septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.
    Eur J Clin Microbiol; 1987 Aug; 6(4):460-6. PubMed ID: 3117535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What do beta-lactamases mean for clinical efficacy?
    Neu HC
    Infection; 1983; 11 Suppl 2():S74-80. PubMed ID: 6423546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lactamases: current situation and clinical importance.
    Garau J
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S5-9. PubMed ID: 7962990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefpirome against beta-lactamase-inducible and stably derepressed Enterobacteriaceae.
    Binfiglio G; Stefani S; Nicoletti G
    Chemotherapy; 1994; 40(5):311-6. PubMed ID: 7956454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible type I beta-lactamases of gram-negative bacteria and resistance to beta-lactam antibiotics.
    Curtis NA; Eisenstadt RL; Rudd C; White AJ
    J Antimicrob Chemother; 1986 Jan; 17(1):51-61. PubMed ID: 3485092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of resistance in gram-negative bacilli during beta-lactam therapy: a challenge for the future.
    Pechère JC
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S17-23. PubMed ID: 2693106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and characterization of cefepime-resistant gram-negative bacteria.
    Piddock LJ; Griggs DJ
    J Antimicrob Chemother; 1991 Nov; 28(5):669-76. PubMed ID: 1778870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of extended spectrum beta lactamases production with cephalosporin resistance in gram negative bacilli.
    Ghatole M; Manthalkar P; Kandle S; Yemul V; Jahagirdar V
    Indian J Pathol Microbiol; 2004 Jan; 47(1):82-4. PubMed ID: 15471144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.
    Sanders CC; Sanders WE
    Rev Infect Dis; 1983; 5(4):639-48. PubMed ID: 6353526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactam resistance in Aeromonas spp. caused by inducible beta-lactamases active against penicillins, cephalosporins, and carbapenems.
    Bakken JS; Sanders CC; Clark RB; Hori M
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1314-9. PubMed ID: 3264129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to third generation cephalosporins: the current situation.
    Pechère JC
    Infection; 1989; 17(5):333-7. PubMed ID: 2689351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefoxitin sensitivity as a marker for inducible beta-lactamases.
    Moritz VA; Carson PB
    J Med Microbiol; 1986 May; 21(3):203-7. PubMed ID: 3486293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.